The use of the Hungarian Test Your Memory (TYM-HUN), MMSE, and ADAS-Cog tests for patients with mild cognitive impairment (MCI) in a Hungarian population: a cross-sectional study
BMC Psychiatry volume 20, Article number: 571 (2020)
Mild cognitive impairment (MCI) often presages the development of Alzheimer’s disease (AD). Accurate and early identification of cognitive impairment will substantially reduce the burden on the family and alleviate the costs for the whole society. There is a need for testing methods that are easy to perform even in a general practitioner’s office, inexpensive and non-invasive, which could help the early recognition of mental decline. We have selected the Test Your Memory (TYM), which has proven to be reliable for detecting AD and MCI in several countries. Our study was designed to test the usability of the Hungarian version of the TYM (TYM-HUN) comparing with the Mini-Mental State Examination (MMSE) and the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in MCI recognition in the Hungarian population.
TYM test was translated and validated into Hungarian (TYM-HUN) in a previous study. The TYM-HUN test was used in conjunction with and compared with the MMSE and the ADAS-Cog. For our study, 50 subjects were selected: 25 MCI patients and 25 healthy controls (HC). Spearman’s rank correlation was used to analyse the correlation between the scores of MMSE and ADAS-Cog with TYM-HUN and the receiver operating characteristic (ROC) curve was established.
MCI can be distinguished from normal aging using TYM-HUN. We established a ‘cut-off’ point of TYM-HUN (44/45points) where optimal sensitivity (80%) and specificity (96%) values were obtained to screen MCI. The total TYM-HUN scores significantly correlated with the MMSE scores (ρ = 0.626; p < 0.001) and ADAS-Cog scores (ρ = − 0.723; p < 0.001).
Our results showed that the TYM-HUN is a reliable, fast, self-administered questionnaire with the right low threshold regarding MCI and can be used for the early diagnosis of cognitive impairment.
Having regard to the global burden of dementia, comprehensive research on possible instruments to properly determine cognitive decline has received a great amount of interest.
The mild cognitive impairment (MCI), which can be considered as a prodrome of dementia, has no universal diagnostic criteria but the following considerations are generally accepted: memory complaint; memory impairment for age and education; preserved general cognitive functions; intact activities of daily living. In contrast, in dementia everyday functionality is no longer maintained and significant cognitive impairment occurs in one or more areas [1,2,3,4,5].
Dementia is a disease that afflicts a large proportion of the elderly. The WHO estimates that it affects around 50 million people worldwide and that there are around 10 million new cases a year .
The process of developing dementia may remain clinically unnoticed for a long time: the onset of molecular pathology can precede the onset of symptoms by up to 20 years. To intervene effectively and promptly, we need to recognize dementia before it fully develops clinically .
In light of this, it is increasingly crucial to have appropriate screening instruments available that are sufficiently accurate and have convenient merits in the early identification of cognitive deficit. These should preferably be screening tests that have outstanding sensitivity and specificity in the identification of cognitive impairment at the early stage including MCI and mild dementia.
The most commonly used procedures in Hungary for the identification of AD are the Mini-Mental State Exam (MMSE) and the Early Mental Test developed by the University of Szeged [8, 9]. There is no international consensus on which is the best test and with which cut-off points. In recent years, the Montreal Cognitive Assessment (MoCA)  and the Short Test of Mental Status  have been used for this purpose, the Hungarian version of which is not yet available .
The MMSE has been shown to be particularly useful in identifying dementia with a short filling time (around 5–10 min). In a systematic review, the authors found that the sensitivity and specificity of MMSE were 0.81 and 0.89 respectively . Janka et al. translated and validated it into Hungarian, the cut-off point they established was 24 . However, it is unreliable in the early detection and not suitable for distinguishing healthy people from those with MCI .
For this purpose, Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) , which has more reliable properties but is more time-consuming (about 35 to 45 min depending on the number and the extent of cognitive areas affected) is used . Although the potential for improvement of the test is raised by a large literature review, it is acknowledged that the ADAS-Cog is a useful measurement instrument in pre-dementia syndromes . In its Hungarian validated form, outstandingly high values were found in the separation of healthy people from AD patients . Both the sensitivity and the specificity are quite high at the mathematically optimal decision point of 12.15, respectively 96.97 and 91.49%.
We have selected a short, self-administered test developed by the English author Jeremy Brown, which is validated in different countries worldwide, also in Hungary (TYM-HUN) [20, 21]. This is the Test Your Memory (TYM), which examines a fairly wide range of cognitive functions (orientation, attention, executive functions, language, memory, and visuospatial skills) in a short period of time (5–10 min) and provides reliable information to the clinician when properly evaluated . The TYM-HUN test, which was previously translated into Hungarian and validated, was found to be reliably used to screen for dementia using a 35/36 cut-off, with which both the sensitivity and specificity of the test were found to be 94% .
The goal of this study was to compare the diagnostic utility of the TYM-HUN with the MMSE and the ADAS-Cog tests for MCI in a Hungarian population. We determined a ‘cut-off’ point of TYM-HUN where optimal sensitivity and specificity values were obtained to screen MCI.
Inclusion and exclusion criteria
Fifty persons, 25 MCI patients and 25 healthy controls (HC), were recruited into the observational cross-sectional study at the Psychiatric Clinic and Hospital of the University of Debrecen between January 2018 and August 2019. Adults (patients/HCs) from the age of 18 and over were included. The diagnosis of MCI was made according to the DSM-5 diagnostic criteria for mild neurocognitive disorders . Patients were seen and diagnosed by a consultant psychiatrist and underwent neurological assessment, MMSE, ADAS-Cog, structural imaging [e.g. computed tomography (CT), magnetic resonance imaging (MRI)], and blood tests. According to the structural imaging results and the laboratory tests, there was no evidence of neurovascular disease or other neurological or systemic diseases. To avoid possible bias due to mood depression, subjects for whom the Beck Depression Inventory (BDI) indicated the presence of depressive symptoms were excluded from further investigation.
HCs were recruited from relatives accompanying patients to the clinic and the hospital, as well as from relatives of patients attending psychiatric outpatients’ departments at these two institutions. The people with a history of neurological disease, memory problems, or brain injury were excluded from the HC group. HCs were included based on the absence of the symptoms, that met the diagnostic criteria for mild neurocognitive disorder (DSM-5) . All participants gave written informed consent and they filled out all our questionnaires completely.
TYM test was translated into Hungarian language and validated for AD (TYM-HUN) . The MMSE, ADAS-Cog, and TYM-HUN tests, and to exclude the depression, the BDI was filled out by the patients and controls, as well.
The age distribution for normality of the sample was tested with the Shapiro-Wilk test and the age difference between the MCI patients and controls was tested with the Mann-Whitney-Wilcoxon rank sum test. We used Fisher’s exact test to investigate the gender distribution and the Kruskal-Wallis test for testing the educational differences.
Spearman’s rank correlation was used to investigate the correlations between the different tests. The receiver operating characteristic (ROC) curve, the sensitivity, specificity, positive (PPV) and negative predictive values (NPV), Youden Index, and area under the curve (AUC) were also established.
We performed the statistical analyses with STATA 11.1 software (Statacorp LP. College Station, TX, USA).
We evaluated the TYM-HUN results of 50 adults aged 55–84 years. Twenty-five MCI patients (mean age 74.84 ± 6.22 years) and 25 HC participants (mean age 71.32 ± 7.69 years) were investigated. The male to female ratios were 6:19 and 8:17 in the MCI and HC groups, respectively. The MCI patients reached an average score of 39.52 ± 5.73/25 on the TYM-HUN, 26.32 ± 2.98/25 points on the MMSE, and 16.80 ± 6.11/25 on the ADAS-Cog tests. The average results of the HC group members were 47.40 ± 1.68/25 with the TYM-HUN, 29.04 ± 1.06/25 with the MMSE, and 5.80 ± 3.64/25 with the ADAS-Cog tests. We also calculated the median scores and the interquartile ranges (IQR) of the tests (MMSE, ADAS-Cog, and TYM-HUN) and these are presented in Fig. 1.
The age distribution of the sample was significantly (p < 0.001) different from the normal distribution, and no significant (p = 0.057) difference was observed between the MCI and HC group’s mean age. There was no significant difference between the gender distribution of the two groups (p = 0.754). These calculations suggest that our sample was comparable with respect to age and gender. In the case of patients with MCI, no significant difference was found between the subjects’ mean TYM-HUN score when comparing them according to their gender (male = 43.33, female = 38.32, p = 0.060). There were no significant differences between when the educational level was analysed (primary = 38.00; secondary = 38.60; tertiary = 41.55; p = 0.467).
Spearman’s rank correlation was used to analyse the correlation between the scores of MMSE and ADAS-Cog with TYM-HUN. The total TYM-HUN scores significantly correlated with the MMSE scores (ρ = 0.626; p < 0.001) and ADAS-Cog scores (ρ = − 0.723; p < 0.001). Negative correlation can be seen between ADAS-Cog and MMSE (ρ = − 0.67, p < 0.001). (Fig. 2).
According to the Youden Index (Y = 76.00%) and the square of the distance (d2 = 4.16%), the ideal cut-off score should be at 44/45 between HC and MCI patients (Table 1). With this cut-off point the true positive rate is 80.00%, the true negative rate is 96,00%, the PPV is 95,24% and the NPV is 82,76%. If this cut-off is applied, then according to our sample the area under the ROC curve is 93,20%. The ROC curve, that was created based on the TYM-HUN scores using the presence/absence of MCI as the criterion variable, is presented in Fig. 3.
The increasing number of the patient with dementia and MCI, the financial and social burdens of these diseases made it necessary, to investigate the possibilities of the earliest detection of the pathological cognitive impairment.
Whilst the Hungarian version of the MMSE is a good diagnostic test for AD, it is not sensitive to detect MCI . The ADAS-Cog can be used to distinguish AD and normal aging however it takes a long time to administer (35–45 min) .
According to our findings, the TYM-HUN seems to be a useful tool for the early detection of the MCI. The correlations we found are as strong as we expected between the different measuring instruments.
As Julayanon  pointed out, MoCA’s superiority over MMSE in its sensitivity probably stems from a deeper, more detailed, more in-depth examination of delayed recall. MoCA and TYM have very similar qualities in the study of this cognitive function, perhaps if possible, TYM is even more sensitive in this area: more words to recall (6 to 5) and the same learning trials (2) and similar time between immediate and delayed recall (5 min). This phenomenon’s validity is corroborated by the observation that this function is impaired in the early stages of the disease. This assumption is supported by numerous prominent authors [7, 17, 24, 25]. In the previous validation, we found that the reliable cut-off point for dementia detection was 35/36 . This correlates roughly with that the memory subtest, the subtest for the most impaired cognitive area in amnestic MCI (aMCI), in the TYM-HUN test counts 9 points and the ideal cut-off we found for MCI detection was 44/45. This link is hard to miss and it can be admitted that the two may have been connected.
There are other instruments applied to screen for dementia or MCI, such as Self-Administered Gerocognitive Examination (SAGE)  or Cognitive Assessment Screening Test (CAST) . The SAGE is a brief cognitive assessment instrument developed in 2010 that is also self-administered and takes about 15 min to complete, and the developers, with a relatively low number of cases, found it particularly useful in detecting MCI: sensitivity 79%, specificity 95% . SAGE is mostly used for community screening and is usually not included in the compilation of major reviews of screening tests . CAST is also a self-administered screening test with advantageous properties with reasonably high sensitivity (88–95%) and specificity (88–100%) . It takes about 15 min to complete. Studies with a relatively low number of cases are available, and is primarily not of diagnostic value, but is suitable for raising the possibility of further investigations . According to our results, while the TYM-HUN is also self-administered and has almost the same characteristics regarding sensitivity (80%) and specificity (96%), it examines many aspects of the cognitive functions in a shorter time (5–10 min) so it can be used outside the hospital settings, for example in the primary care or family medicine practices. Moreover, a telephone version of the TYM test has been developed which makes it easier to reach the patients .
We compared the results we obtained with other nations’ findings regarding the usability of TYM in recognizing MCI. While MCI subjects had an average score of 45 in the original publication, our study found it to be 39.52 . In studies conducted in Chile and Japan have found that the 44-points cut-off value is appropriate to distinguish between HC and MCI which is similar to our result. Based on these results, the test has 85.7 and 76% sensitivity, 69 and 74% specificity respectively in the above-mentioned studies, while our results show that these values are 80 and 96% [31, 32]. Polish and French investigators did not find the test useful in differentiating between MCI and HC [33, 34].
Japanese researchers in a larger sample, like us, found no significant difference in test scores with regard to gender and education level . According to French data, there is no correlation between gender and years spent in education (p = 0.34) and performance on TYM, but this can be observed regarding age (p = 0.004) . According to the Chilean study, the performance was influenced by the highest level of education (β coefficient = 0.31, p < 0.001), but age (p = 0.849) had no relation to performance on the TYM test . The Polish study (which divided the subjects into two groups according to age and set the dividing line at 75 years) found that age (p < 0.003) and the number of years of education (p < 0.001) influence the score on TYM .
One of the main strengths of our study is that the TYM-HUN test is the first short, self-administered test in Hungarian language, that can detect MCI. The ADAS-Cog is also sensitive enough, but the administration of the ADAS-Cog is time-consuming and it is difficult to use in the everyday outpatient and primary care settings.
The limitation of the study is the relatively low number of cases, but in most of the other studies (especially from small countries, like Hungary) the clinicians could not find a lot of patients with suspected MCI and who fit the inclusion criteria and are willing to take part in the study. The refusal of the patients had been one of the greatest challenges, maybe because they do not have a sense of illness or do not want to know about the MCI or early stage of AD or fearing the stigmatization.
The TYM-MCI is a recently developed test for the distinguishment of aMCI and normal, and because of its novelty, it is not yet widespread. Although this specially developed version of the test is available for the detection of MCI with a sensitivity of 0.79 and specificity of 0.91, according to our study, TYM-HUN alone can detect patients with MCI in a Hungarian sample .
Summarizing, the TYM-HUN test is a reliable and easy-to-administer tool for assessing people with suspected MCI in Hungarian language. The adapted versions into different languages of the TYM test can be useful tools to recognize the early stages of dementia in hospital, outpatient, and primary care settings and make an international comparison between the countries’ population regarding the different forms of cognitive impairment, as well.
Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.
Alzheimer’s Disease Assessment Scale-Cognitive Subscale
Amnestic mild cognitive impairment
Area under the curve
Beck Depression Inventory
Cognitive Assessment Screening Test
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
Mild cognitive impairment
Mini-Mental State Examination
Montreal Cognitive Assessment
Magnetic resonance imaging
Negative predictive value
Positive predictive value
Receiver operating characteristic
Self-administered Gerocognitive Examination
Test Your Memory
Hungarian version of the Test Your Memory
World Health Organization
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.
Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI working Group of the European Consortium on Alzheimer's disease. Journal of neurology. Neurosurg Psychiatry. 2006;77:714–8.
Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–9.
Mild cognitive impairment (MCI). Mayo Clinic. Mayo Foundation for Medical Education and Research; 2020. Available from: https://www.mayoclinic.org/diseases-conditions/mild-cognitive-impairment/diagnosis-treatment/drc-20354583?_ga=2.138240880.1960211841.1572084265-141017451.1570595539.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.): Arlington; 2013.
Dementia. World Health Organization. World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia.
Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol. 2004;3:246–8.
Folstein MF, Folstein SE, Mchugh PR. Mini-mental state. J Psychiatr Res. 1975;12:189–98.
Kálmán J, Pákáski M, Hoffmann I, Drótos G, Darvas G, Boda K, Bencsik T, Gyimesi A, Gulyás Z, Bálint M, Szatlóczki G, Papp E. Early mental test--developing a screening test for mild cognitive impairment. Ideggyógy Sz. 2013;66(01–02):43–52.
Nasreddine ZS, Phillips NA, Bédirian VR, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.
Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc. 1987;62:281–8.
Petersen RC. Mild cognitive impairment. Continuum (Minneap Minn). 2016;22:404–18.
Tsoi KKF, Chan JYC, Hirai HW, Wong SYS, Kwok TCY. Cognitive tests to detect dementia. JAMA Intern Med. 2015;175:1450.
Janka Z, Somogyi A, Maglóczky E, Pakaski M, Kálmán J. Dementia screening by a short cognitive test. Orv Hetil. 1989;129:2797–800.
Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res. 2009;43:411–31.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatr. 1984;141:1356–64.
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett D, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and Normal aging for clinical trials. Arch Neurol. 2004;61:59.
Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer’s disease assessment scale–cognitive subscale (ADAS-cog): modifications and responsiveness in pre-dementia populations. A narrative review. J Alzheimers Dis. 2018;63:423–44.
Pákáski M, Drótos G, Janka Z, Kálmán J. Validation of the Hungarian version of Alzheimer’s disease assessment scale – cognitive subscale. Orv Hetil. 2012;153:461–6.
Brown JM, Wiggins J, Dawson K, Rittman T, Rowe JB. Test your memory (TYM) and test your memory for mild cognitive impairment (TYM-MCI): a review and update including results of using the TYM test in a general neurology clinic and using a telephone version of the TYM test. Diagnostics. 2019;9:116.
Kolozsvári LR, Kovács ZG, Szőllősi GJ, Harsányi S, Frecska E, Égerházi A. Validation of the Hungarian version of the test your memory. Ideggyógy Sz. 2017;70:267–72.
Brown J, Pengas G, Dawson K, Brown LA, Clatworthy P. Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study. Bmj. 2009;338:b2030.
Julayanont P, Nasreddine ZS. Montreal Cognitive Assessment (MoCA): Concept and Clinical Review. In: Cognitive Screening Instruments. Edited by Larner AJ. Cham; Springer; 2017. p. 139–5. Avaliable from: https://doi.org/10.1007/978-3-319-44775-9_7.
Tsoi KK, Chan JY, Hirai HW, Wong A, Mok VC, Lam LC, et al. Recall Tests Are Effective to Detect Mild Cognitive Impairment: A Systematic Review and Meta-analysis of 108 Diagnostic Studies. J Am Med Dir Assoc. 2017;18(9):807.e17–29.
Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230–8.
Scharre DW, Chang S-I, Murden RA, Lamb J, Beversdorf DQ, Kataki M, et al. Self-administered Gerocognitive examination (SAGE). Alzheimer Dis Assoc Disord. 2010;24:64–71.
Drachman DA, Swearer JM, Kane K, Osgood D, O'toole C, Moonis M. The cognitive assessment screening test (CAST) for dementia. J Geriatr Psychiatry Neurol. 1996;9:200–8.
Scharre DW, Chang SI, Nagaraja HN, Yager-Schweller J, Murden RA. Community cognitive screening using the self-administered Gerocognitive examination (SAGE). J Neuropsychiatr Clin Neurosci. 2014;26:369–75.
Cherbuin N, Anstey KJ, Lipnicki DM. Screening for dementia: a review of self- and informant-assessment instruments. Int Psychogeriatr. 2008;20(3):431–58.
Velayudhan L, Ryu S-H, Raczek M, Philpot M, Lindesay J, Critchfield M, et al. Review of brief cognitive tests for patients with suspected dementia. Int Psychogeriatr. 2014;26:1247–62.
Muñoz-Neira C, Chaparro FH, Delgado C, Brown J, Slachevsky A. Test your memory-Spanish version (TYM-S): a validation study of a self-administered cognitive screening test. Int J Geriatric Psychiatry. 2014;29:730–40.
Hanyu H, Maezono M, Sakurai H, Kume K, Kanetaka H, Iwamoto T. Japanese version of the test your memory as a screening test in a Japanese memory clinic. Psychiatry Res. 2011;190:145–8.
Szczesniak D, Wojtynska R, Rymaszewska J. Test your memory (TYM) as a screening instrument in clinical practice – the polish validation study. Aging Ment Health. 2013;17:863–8.
Postel-Vinay N, Hanon O, Clerson P, Brown JM, Ménard J, Paillaud E, et al. Validation of the test your memory (F-TYM test) in a French memory clinic population. Clin Neuropsychol. 2014;28:994–1007.
Brown JM, Lansdall CJ, Wiggins J, Dawson KE, Hunter K, Rowe JB, et al. The test your memory for mild cognitive impairment (TYM-MCI). J Neurol Neurosurg Psychiatry. 2017;88:1045–51.
We would like to thank the permission to use the TYM test and the kind support of Jeremy.
Brown. Also like to thank the patients, doctors and all participants in our study.
This research did not receive any specific grant from funding agencies in the public,
commercial, or not-for-profit sectors.
Ethics approval and consent to participate
The ethical permission was approved by the Hajdu-Bihar County’s Government Office of Public Health’s Services according to the recommendations of the Regional and Institutional Research Ethics Committee of the Medical and Health Science Centre of the University of Debrecen (Number of permission: DE OEC RKEB/IKEB 3852–2013), and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
Informed written consent was obtained from all patients for being included in the study and all persons gave their written informed consent prior to their inclusion in the study.
Consent for publication
The manuscript does not contain data from any individual person, this section is “Not applicable”.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Garbóczy, S., Magócs, É., Szőllősi, G.J. et al. The use of the Hungarian Test Your Memory (TYM-HUN), MMSE, and ADAS-Cog tests for patients with mild cognitive impairment (MCI) in a Hungarian population: a cross-sectional study. BMC Psychiatry 20, 571 (2020). https://doi.org/10.1186/s12888-020-02982-6